| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer
|
Vaishampayan, Ulka N.
|
|
|
202 |
C |
p.
|
artikel
|
| 2 |
A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness
|
Yoshino, Takayuki
|
|
|
202 |
C |
p.
|
artikel
|
| 3 |
A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability
|
Moreau, Mathilde
|
|
|
202 |
C |
p.
|
artikel
|
| 4 |
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
|
Albrecht, Lea Jessica
|
|
|
202 |
C |
p.
|
artikel
|
| 5 |
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
|
Wei, Xiaoting
|
|
|
202 |
C |
p.
|
artikel
|
| 6 |
A recurrent NTRK1 tyrosine kinase domain mutation pair is characteristic in a subset of dedifferentiated liposarcomas
|
Lippai, Zoltán
|
|
|
202 |
C |
p.
|
artikel
|
| 7 |
Assessing the clinical benefit of systemic anti-cancer treatments in the Netherlands: The impact of different thresholds for effectiveness
|
Leeneman, Brenda
|
|
|
202 |
C |
p.
|
artikel
|
| 8 |
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma
|
Sacco, Joseph J.
|
|
|
202 |
C |
p.
|
artikel
|
| 9 |
Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)
|
Roth, Gael S.
|
|
|
202 |
C |
p.
|
artikel
|
| 10 |
Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?
|
Raiser, Patricia
|
|
|
202 |
C |
p.
|
artikel
|
| 11 |
Cisplatin shortage results in substitution of more expensive treatments: Drug cost analysis
|
Lam, Michael
|
|
|
202 |
C |
p.
|
artikel
|
| 12 |
Clinical and prognostic differences in oropharyngeal squamous cell carcinoma in USA and Denmark, two HPV high-prevalence areas
|
Carlander, Amanda-Louise Fenger
|
|
|
202 |
C |
p.
|
artikel
|
| 13 |
Clinical care pathways of patients with biliary tract cancer: A French nationwide longitudinal cohort study
|
Tzedakis, Stylianos
|
|
|
202 |
C |
p.
|
artikel
|
| 14 |
Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer
|
Boidot, Romain
|
|
|
202 |
C |
p.
|
artikel
|
| 15 |
Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma
|
Cao, Hang
|
|
|
202 |
C |
p.
|
artikel
|
| 16 |
Comment on: Despite multi-disciplinary team discussions the socioeconomic disparities persist in the oncological treatment of non-metastasized colorectal cancer
|
Li, Liqi
|
|
|
202 |
C |
p.
|
artikel
|
| 17 |
Corrigendum to “Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer” Eur. J. Cancer (201) (April) 2024, 113913
|
Gravbrot, Nicholas
|
|
|
202 |
C |
p.
|
artikel
|
| 18 |
Corrigendum to “Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial” [Eur J Cancer 199 (2024) 113531]
|
Di Giacomo, Anna Maria
|
|
|
202 |
C |
p.
|
artikel
|
| 19 |
Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis
|
Untch, Michael
|
|
|
202 |
C |
p.
|
artikel
|
| 20 |
Editorial Board
|
|
|
|
202 |
C |
p.
|
artikel
|
| 21 |
EORTC QLQ-C30 general population normative data for the United States
|
Rogge, Alizé A.
|
|
|
202 |
C |
p.
|
artikel
|
| 22 |
Evolution of clinical nature, treatment and survival of locally recurrent rectal cancer: Comparative analysis of two national cross-sectional cohorts
|
van Geffen, E.G.M.
|
|
|
202 |
C |
p.
|
artikel
|
| 23 |
Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors
|
Helgadottir, Hildur
|
|
|
202 |
C |
p.
|
artikel
|
| 24 |
FGF amplification an important targeted for head and neck cancer patient? A case report of a patient with FGF amplification treated with erdafitinib
|
Gibson, Nyere
|
|
|
202 |
C |
p.
|
artikel
|
| 25 |
How to develop new systemic treatments in ultra-rare cancers with high unmet needs? The case of alveolar soft-part sarcoma
|
Stacchiotti, Silvia
|
|
|
202 |
C |
p.
|
artikel
|
| 26 |
Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients
|
Barbe, Rémy
|
|
|
202 |
C |
p.
|
artikel
|
| 27 |
Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium
|
Bührer, Emanuel
|
|
|
202 |
C |
p.
|
artikel
|
| 28 |
Novel use of abatacept and ruxolitinib as salvage therapy in steroid-refractory immune checkpoint blockade-induced myocarditis with myasthenia and myositis overlap syndrome
|
Byer, Stefano H.
|
|
|
202 |
C |
p.
|
artikel
|
| 29 |
Obituary: Nobel Laureate Harald zur Hausen (1936–2023) - Who dedicated his life to unraveling the role of infectious agents in the pathogenesis of human cancers
|
Baumann, Michael
|
|
|
202 |
C |
p.
|
artikel
|
| 30 |
Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma
|
Holmstroem, Rikke B.
|
|
|
202 |
C |
p.
|
artikel
|
| 31 |
Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations
|
Hertz, Daniel L.
|
|
|
202 |
C |
p.
|
artikel
|
| 32 |
Performance of an automated total body mapping algorithm to detect melanocytic lesions of clinical relevance
|
Winkler, Julia K.
|
|
|
202 |
C |
p.
|
artikel
|
| 33 |
Prognosis of glioblastoma patients improves significantly over time interrogating historical controls
|
Thomas-Joulié, A.
|
|
|
202 |
C |
p.
|
artikel
|
| 34 |
Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: A nationwide, population-based cohort study
|
Wagner, Thomas
|
|
|
202 |
C |
p.
|
artikel
|
| 35 |
Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
|
Roussot, Nicolas
|
|
|
202 |
C |
p.
|
artikel
|
| 36 |
Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials
|
Lesan, Vadim
|
|
|
202 |
C |
p.
|
artikel
|
| 37 |
Propranolol monotherapy in angiosarcoma – A window-of-opportunity study (PropAngio)
|
Embaby, Alaa
|
|
|
202 |
C |
p.
|
artikel
|
| 38 |
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
|
Leonetti, Alessandro
|
|
|
202 |
C |
p.
|
artikel
|
| 39 |
Response to Letter RE: Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study
|
Debets, Pien
|
|
|
202 |
C |
p.
|
artikel
|
| 40 |
REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas
|
Picca, Alberto
|
|
|
202 |
C |
p.
|
artikel
|
| 41 |
Scaling up and implementing the digital Survivorship Passport tool in routine clinical care – The European multidisciplinary PanCareSurPass project
|
Filbert, Anna-Liesa
|
|
|
202 |
C |
p.
|
artikel
|
| 42 |
Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy
|
Kött, Julian
|
|
|
202 |
C |
p.
|
artikel
|
| 43 |
Survival of European adolescents and young adults diagnosed with cancer in 2010–2014
|
Trama, Annalisa
|
|
|
202 |
C |
p.
|
artikel
|
| 44 |
Survival trends for patients diagnosed with cutaneous malignant melanoma in the Nordic countries 1990-2016: The NORDCAN survival studies
|
Lundberg, Frida E.
|
|
|
202 |
C |
p.
|
artikel
|
| 45 |
The European Network for Sinonasal Cancer Research (EUSICA) – A pan-European initiative targeting a group of orphan tumours
|
Hermsen, Mario
|
|
|
202 |
C |
p.
|
artikel
|
| 46 |
The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations
|
Schaper-Gerhardt, Katrin
|
|
|
202 |
C |
p.
|
artikel
|
| 47 |
Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study
|
Kennedy, Oliver John
|
|
|
202 |
C |
p.
|
artikel
|
| 48 |
Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP)
|
Spiekman, Ilse A.C.
|
|
|
202 |
C |
p.
|
artikel
|
| 49 |
UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – A phase II randomised trial
|
Haakensen, Vilde Drageset
|
|
|
202 |
C |
p.
|
artikel
|
| 50 |
Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study
|
You, Liangshun
|
|
|
202 |
C |
p.
|
artikel
|
Tijdschrift beschrijving